Insider Transactions in Q1 2025 at Solid Biosciences Inc. (SLDB)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Bain Capital Life Sciences Investors, LLC |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+16.57%
|
$4,000,000
$4.03 P/Share
|
|
Feb 19
2025
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
5,000,000
+29.7%
|
$20,000,000
$4.03 P/Share
|
|
Feb 18
2025
|
Adage Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
252,545
+5.61%
|
$1,767,815
$7.56 P/Share
|
|
Feb 14
2025
|
Ilan Ganot |
SELL
Open market or private sale
|
Indirect |
1,711
-10.34%
|
$5,133
$3.96 P/Share
|
|
Feb 14
2025
|
Alexander Cumbo President and CEO |
SELL
Open market or private sale
|
Direct |
11,365
-15.77%
|
$34,095
$3.96 P/Share
|
|
Feb 14
2025
|
David T Howton Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,561
-18.32%
|
$16,683
$3.96 P/Share
|
|
Feb 14
2025
|
Paul Herzich Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,688
-12.75%
|
$8,064
$3.96 P/Share
|
|
Feb 14
2025
|
Kevin Tan CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
3,164
-8.93%
|
$9,492
$3.96 P/Share
|
|
Feb 14
2025
|
Gabriel Brooks Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,256
-12.49%
|
$9,768
$3.96 P/Share
|
|
Feb 14
2025
|
Jessie Hanrahan Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
3,079
-13.77%
|
$9,237
$3.96 P/Share
|
|
Feb 13
2025
|
Ilan Ganot |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,861
+22.7%
|
-
|
|
Feb 13
2025
|
Alexander Cumbo President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,031
+29.41%
|
-
|
|
Feb 13
2025
|
David T Howton Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,687
+32.61%
|
-
|
|
Feb 13
2025
|
Paul Herzich Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,187
+25.43%
|
-
|
|
Feb 13
2025
|
Kevin Tan CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,625
+23.08%
|
-
|
|
Feb 13
2025
|
Gabriel Brooks Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,937
+29.56%
|
-
|
|
Feb 13
2025
|
Jessie Hanrahan Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,125
+26.65%
|
-
|
|
Jan 28
2025
|
Ilan Ganot |
SELL
Open market or private sale
|
Indirect |
144
-1.22%
|
$432
$3.11 P/Share
|
|
Jan 27
2025
|
Ilan Ganot |
BUY
Exercise of conversion of derivative security
|
Direct |
3,883
+3.79%
|
-
|
|
Jan 27
2025
|
Ilan Ganot |
BUY
Exercise of conversion of derivative security
|
Indirect |
388
+3.17%
|
-
|
|
Jan 10
2025
|
Kevin Tan CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
4,073
-14.11%
|
$12,219
$3.89 P/Share
|
|
Jan 09
2025
|
Kevin Tan CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+28.05%
|
-
|
|
Jan 06
2025
|
Ilan Ganot |
SELL
Open market or private sale
|
Indirect |
1,056
-8.45%
|
$4,224
$4.31 P/Share
|
|
Jan 03
2025
|
Ian F Smith |
BUY
Exercise of conversion of derivative security
|
Direct |
3,255
+2.8%
|
-
|
|
Jan 03
2025
|
Ilan Ganot |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,994
+19.32%
|
-
|